No change in circulating osteoprotegerin levels by intravenous calcitriol therapy among dialysis patients with secondary hyperparathyroidism.
Nishi
H
H
Nii-Kono
T
T
Ikeda
K
K
Fujimori
A
A
Fukagawa
M
M
D002117:Calcitriol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004797:Enzyme-Linked Immunosorbent Assay; D006023:Glycoproteins / Q000097:blood*; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy*; D053244:Osteoprotegerin; D018160:Receptors, Cytoplasmic and Nuclear / Q000097:blood*; D018124:Receptors, Tumor Necrosis Factor / Q000097:blood*; D006435:Renal Dialysis; D016896:Treatment Outcome
D006023:Glycoproteins; D053244:Osteoprotegerin; D018160:Receptors, Cytoplasmic and Nuclear; D018124:Receptors, Tumor Necrosis Factor; C506030:TNFRSF11B protein, human; D002117:Calcitriol; C051883:maxacalcitol